



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/828,344	04/05/2001	C. Frank Bennett	RTS-0147 1718	
7	590 01/13/200		EXAMINER	
Jane Massey Licata Licata & Tyrrell, P.C.			SCHULTZ, JAMES	
66 East Main S		•	ART UNIT	PAPER NUMBER
Marlton, NJ	08053		1635	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	09/828,344	BENNETT ET AL.					
neneer <b>y</b> neaen	Examiner	Art Unit					
	J. D. Schultz, Ph.D.	1635	·				
The MAILING DATE of this communication appe	ars on the cov r sh et with the c	orrespond nce add	ress				
THE REPLY FILED 19 October 2004 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this appliced in the contract which is a supplication with the contract with the c	cation. A proper rep ch places the applic	ply to a cation in				
PERIOD FOR RE	PLY [check either a) or b)]						
a) The period for reply expires 4 months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Adviewent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The dath have been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mo	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THE see on which the petition under 37 CFR 1.1 sion and the corresponding amount of the statutory period for reply originally set in a second content of the statutory period for reply originally set in a second content of the statutory period for reply originally set in a second content of the statutory period for reply originally set in a second content of the second	the final rejection. FINAL REJECTION. S  36(a) and the appropriate ext fee. The appropriate ext the final Office action; or	See MPEP e extension fee tension fee under (2) as set forth in				
earned patent term adjustment. See 37 CFR 1.704(b).		,,,,,	,				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFI							
2. The proposed amendment(s) will not be entered because:							
(a) 🛛 they raise new issues that would require further	er consideration and/or search (	see NOTE below);					
(b) ☐ they raise the issue of new matter (see Note below);							
<ul><li>(c)  they are not deemed to place the application i issues for appeal; and/or</li></ul>	n better form for appeal by mate	erially reducing or s	implifying the				
(d) they present additional claims without cancel	ing a corresponding number of t	finally rejected clair	ns.				
NOTE: <u>See Continuation Sheet</u> .							
3. Applicant's reply has overcome the following rejection	tion(s): 35 U.S.C. § 102/103.						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	eparate, timely filed	d amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See	reconsideration has been cons <u>e Continuation Sheet</u> .	idered but does NC	T place the				
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which we	re newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed: <u>4-10,13 and 15</u> .							
Claim(s) objected to:							
Claim(s) rejected: 1, 2, 12, and 14 for the same reason	ons of record set forth 24 June 200	<u>4</u> .					
Claim(s) withdrawn from consideration:							
8. The drawing correction filed on is a) applied applied on is a)	roved or b) disapproved by	the Examiner.					
9. Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s)						
10. Other:							
	·						

Application No.

Applicant(s)

Continuation of 2. NOTE: Applicants proposed amendment seeks to re-introduce material canceled during prosecution in response to a rejection and its entry thus requires further considerations. Claim 15, although not mark d as an amend d claim in the instant amendment, has been amended to delete language drawn to the use of the instantly claimed antisense nucleic acids in vitro, such that the newly claimed method encompasses in vivo use. Such claim language encompassing in vivo use was previously the subject of a rejection under 35 U.S.C. § 112 first paragraph enablement, and was canceled by applicant to obviate said rejection. Its attempted reintroduction raises these issues anew, and its entry is therefore denied. As a side note, it is noted that claim 15 is labeled as "previously presented". While the exact language applicants seek to re-introduce indeed was "previously presented" as an original claim, said claim is amended in the proposed amendment from the immediately preceding amendment, and should be labeled "currently amended". Per 37 CFR 1.121 "When claim text with markings is required. All claims being currently amended in an amendment paper shall be presented in the claim listing, indicate a status of "currently amended," and be submitted with markings to indicate the changes that have been made relative to the immediate prior version of the claims." Accordingly, applicants submission is not in compliance with 37 CFR 1.121.

Continuation of 5. does NOT place the application in condition for allowance because: the arguments therein are drawn exclusively to the claims as recited in the proposed amendment. Because the amendment will not be entered for the reasons provided above, arguments directed to claims not entered will not be considered.

JOAN L. LEW ADER
SUPER S

JOHN L. LEGUYADER SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600